Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin-ESHAP vs ESHAP in Relapsed/Refractory Classical Hodgkin Lymphoma
2024-516149-38-00Phase 2Authorised
- Sponsor
- GELTAMO
- Start
- Oct 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of brentuximab vedotin in Hodgkin lymphoma (HL) (2 arms), sponsored by GELTAMO. Primary endpoint: Metabolic complete response rate after salvage therapy. Planned start Oct 2024; status: authorised.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2024-516149-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516149-38-00.